To date, two menin-MLL1 inhibitors (K0539, NCT04067336 and SNDX-5613, NCT04065399) have demonstrated preclinical activity in HOXA/MEIS1 genes-driven leukemias, including MLL-r and NPM1-mutant AML, and have entered clinical testing with a focus on patients with MLL-rearrangements or NPM1 mutations. This evidence concerns the gene NPM1 and leukemia.